TNFRSF10A: A Potential Drug Target Or Biomarker (G389641)

Target Name: TNFRSF10A-DT

NCBI ID: G389641

TNFRSF10A-DT

Other Name(s): TNFRSF10A divergent transcript | PLACT1

TNFRSF10A: A Potential Drug Target Or Biomarker

TNFRSF10A-DT, also known as TNFRSF10A divergent transcript, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases. The TNFRSF10A gene is a member of the tumor necrosis factor receptor superfamily, which includes a group of cytokines that play a crucial role in cellular signaling and inflammation.

The TNFRSF10A gene is expressed in a variety of tissues and cells throughout the body, including the immune system, tissues, and organs. It is known to be involved in the regulation of cellular processes such as cell adhesion, migration, and survival. The level of expression of the TNFRSF10A gene has also been shown to be associated with the development and progression of certain diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of the TNFRSF10A gene is its ability to induce a pro-inflammatory response in cells. This is accomplished through the interaction of the TNFRSF10A gene with its downstream target, the turnaround RNA (SMN). The SMN protein is a negative regulator of the NF-kappa-B signaling pathway, which is a well-established pathway involved in the regulation of inflammation and immune responses. The interaction between TNFRSF10A and SMN has been shown to play a role in the regulation of cellular processes such as cell survival, migration, and angiogenesis.

In addition to its role in cellular signaling, the TNFRSF10A gene is also of interest as a potential drug target or biomarker because of its potential to modulate the immune response. The TNFRSF10A gene has been shown to play a role in the regulation of T cell development and function, including the regulation of CD4+ and CD8+ T cell responses. The expression of the TNFRSF10A gene has also been shown to be associated with the development of certain autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

The potential utility of the TNFRSF10A gene as a drug target or biomarker is further demonstrated by its potential to treat certain diseases that are currently underserved by effective treatments. For example, the TNFRSF10A gene has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The expression of the TNFRSF10A gene has also been shown to be associated with the development of certain cancers, such as melanoma and colorectal cancer.

In conclusion, the TNFRSF10A gene is a promising candidate for drug targeting or biomarker research due to its involvement in cellular signaling and the regulation of immune responses. Further studies are needed to fully understand the potential utility of the TNFRSF10A gene as a drug target or biomarker .

Protein Name: TNFRSF10A Divergent Transcript

The "TNFRSF10A-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNFRSF10A-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets